Cell Therapy for Parkinson’s Disease

Takao Yasuhara, Masahiro Kameda, Tatsuya Sasaki, Naoki Tajiri, Isao Date

Research output: Contribution to journalReview articlepeer-review

64 Citations (Scopus)


Cell therapy for Parkinson’s disease (PD) began in 1979 with the transplantation of fetal rat dopamine-containing neurons that improved motor abnormalities in the PD rat model with good survival of grafts and axonal outgrowth. Thirty years have passed since the 2 clinical trials using cell transplantation for PD patients were first reported. Recently, cell therapy is expected to develop as a realistic treatment option for PD patients owing to the advancement of biotechnology represented by pluripotent stem cells. Medication using levodopa, surgery including deep brain stimulation, and rehabilitation have all been established as current therapeutic strategies. Strong therapeutic effects have been demonstrated by these treatment methods, but they have been unable to stop the progression of the disease. Fortunately, cell therapy might be a key for true neurorestoration. This review article describes the historical development of cell therapy for PD, the current status of cell therapy, and the future direction of this treatment method.

Original languageEnglish
Pages (from-to)1551-1559
Number of pages9
JournalCell Transplantation
Issue number9
Publication statusPublished - Sept 1 2017


  • ES cells
  • cell therapy
  • dopaminergic neuron
  • iPSCs
  • transplantation

ASJC Scopus subject areas

  • Biomedical Engineering
  • Cell Biology
  • Transplantation


Dive into the research topics of 'Cell Therapy for Parkinson’s Disease'. Together they form a unique fingerprint.

Cite this